Trial · NCT06004037
Study to Evaluate the Efficacy of Delpazolid as Add-on Therapy in Refractory Mycobacterium Abscessus Complex
NCT06004037, Phase 2, Completed, LigaChem Biosciences, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study to Evaluate the Efficacy of Delpazolid as Add-on Therapy in Refractory Mycobacterium Abscessus Complex. Trials, record NCT06004037. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06004037
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study to Evaluate the Efficacy of Delpazolid as Add-on Therapy in Refractory Mycobacterium Abscessus Complex
- NCT number
- NCT06004037
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 24 participants, actual
- Lead sponsor
- LigaChem Biosciences, Inc.
- Conditions
- Nontuberculous Mycobacterium Infection, Mycobacterium Abscessus Infection
- Interventions
- Delpazolid
- First posted
- 2023-08-22
- Last updated
- 2026-07-10
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | semi-quantitative scale (SQS) change versus baseline | 12 weeks | The SQS using liquid media and solid media will be scored a point of 1-7, with lower scores representing a reducing bacterial load. |
| Secondary | Change from baseline in SQS | 4 weeks and 8 weeks | The SQS using liquid media and solid media will be scored a point of 1-7, with lower scores representing a reducing bacterial load. |
| Secondary | Sputum culture conversion rate | 12 weeks | neg culture x3( sputum conversion) |
| Secondary | Time to culture conversion | 12 weeks | from the date of assignment to the first negative result. |
| Secondary | Time to positivity in the liquid culture automated system (MGIT) | 12 weeks | time to detection of positive in MGIT system |
| Secondary | Negative sputum culture rate at each time point after baseline | 12 weeks | negative culture results in MGIT and solid media |
| Secondary | Change from baseline in the inflammatory marker | 12 weeks | erythrocyte sedimentation rate \[ESR\]) at each time point |
| Secondary | Change from baseline in the CT score | 12 weeks | The CT scan score will be transformed onto a scale of 0-42, with lower scores representing improved lung presentations. Descriptive statistics for each point in time are presented, and intra-group comparison of CT score changes at 12 weeks compared to baseline |
| Secondary | Quality of Life Questionnaire-Bronchiectasis | 12 weeks | The QOL-B respiratory symptoms score was transformed onto a scale of 0-100, with higher scores representing a better quality of life. |
| Secondary | Six-minute walk test | 12 weeks | Six-minute walk test |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06004037
GET https://conductscience.org/api/trials/v1/NCT06004037/registered